• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
【24h】

The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.

机译：从辛伐他汀转化为阿托伐他汀对纤溶酶原激活物抑制剂1型的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Plasminogen activator inhibitor type-1 (PAI-1) is an important regulatory component of fibrinolysis and is elevated in the presence of endothelial dysfunction. Endothelial dysfunction and PAI-1 in patients with coronary artery disease (CAD) have been demonstrated to improve following simvastatin therapy. The effect of converting from simvastatin to atorvastatin on PAI-1 has not been reported and may be an additional consideration when making a formulary medication switch. Fourteen adult patients with hypercholesterolemia and CAD who were receiving simvastatin for a minimum of 3 months were randomized to continue on simvastatin or be converted to atorvastatin. Doses were adjusted to achieve or sustain a low-density lipoprotein (LDL) cholesterol of < or = 100 mg/dL. A fasting lipid panel and PAI-1 were obtained at baseline and following 10 weeks of treatment. Mean +/- SD LDL cholesterol at baseline (95.6 +/- 13.8 vs. 87.0 +/- 12.3 dL, p = 0.24) and following 10 weeks of simvastatin or atorvastatin (96.6 +/- 8.9 vs. 87.4 +/- 20.3 mg/dL, p = 0.29) were similar. No differences in PAI-1 were observed at baseline (47.7 +/- 19.3 vs. 64.6 +/- 22.2 ng/mL, p = 0.15) or at 10 weeks (51.1 +/- 32.5 vs. 63.9 +/- 26.9 ng/mL, p = 0.44). These data suggest that the conversion from simvastatin to atorvastatin does not adversely affect PAI-1 plasma concentrations in patients with CAD.
机译：纤溶酶原激活物抑制剂1型（PAI-1）是纤维蛋白溶解的重要调节成分，在存在内皮功能障碍时升高。辛伐他汀治疗后，已证明冠心病（CAD）患者的内皮功能障碍和PAI-1改善。从辛伐他汀到阿托伐他汀的转化对PAI-1的影响尚未见报道，在进行处方药转换时可能是另外的考虑因素。接受辛伐他汀治疗至少3个月的14名成年高胆固醇血症和CAD患者被随机分配继续接受辛伐他汀治疗或转换为阿托伐他汀治疗。调整剂量以达到或维持≤100 mg / dL的低密度脂蛋白（LDL）胆固醇。在基线和治疗10周后获得空腹脂质组和PAI-1。基线时（+/- 95.6 +/- 13.8 vs. 87.0 +/- 12.3 dL，p = 0.24）和辛伐他汀或阿托伐他汀10周后的平均+/- SD LDL胆固醇（96.6 +/- 8.9 vs. 87.4 +/- 20.3 mg / dL，p = 0.29）相似。在基线时（47.7 +/- 19.3 vs. 64.6 +/- 22.2 ng / mL，p = 0.15）或在10周时（51.1 +/- 32.5 vs. 63.9 +/- 26.9 ng / mL）没有观察到PAI-1的差异。 ，p ＝ 0.44）。这些数据表明，从辛伐他汀向阿托伐他汀的转化不会对CAD患者的PAI-1血浆浓度产生不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号